CN1311842C - Medicine for treating chronic conjunctivitis - Google Patents
Medicine for treating chronic conjunctivitis Download PDFInfo
- Publication number
- CN1311842C CN1311842C CNB2005100908597A CN200510090859A CN1311842C CN 1311842 C CN1311842 C CN 1311842C CN B2005100908597 A CNB2005100908597 A CN B2005100908597A CN 200510090859 A CN200510090859 A CN 200510090859A CN 1311842 C CN1311842 C CN 1311842C
- Authority
- CN
- China
- Prior art keywords
- medicine
- eye
- adds
- water
- described medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses a medicine for treating chronic conjunctivitis, which is prepared from honeysuckle, astragalus root, ledebouriella root, pearl, borneol, etc. according to a certain proportion by weight. The medicine can be made into any external application preparation for ophthalmology. The medicine of the present invention has the functions of removing heat to brighten vision, withdrawing erythro and relieving itch. The medicine of the present invention is used for treating the chronic conjunctivitis and has good treating effects on eye discomfort, such as eye dryness, itch pain, eye fatigue, etc.
Description
[technical field]
The present invention relates to a kind of medicine for the treatment of chronic conjunctivitis and preparation method thereof, belong to the field of Chinese medicines.
[background technology]
Chronic conjunctivitis is an ophthalmology common disease, because universal, the air pollution of computer increase the weight of, causes the sickness rate of chronic conjunctivitis to raise year by year in recent years, has become the most common oculopathy of ophthalmology.The dry and astringent pain of itching of the conscious eye of patient, asthenopia, daily life and study and work have been had a strong impact on, the present clinical good active drug that still do not have, common antibiotics, vitamins collyrium and astringent treatment, curative effect is not remarkable, Chinese patent disclosed some methods of using the treatment by Chinese herbs eye conjunctivitis, as: CN1100953, CN1108556, CN1132627, CN1207322, CN89105757.9, being used for that the prescription of these patents is not successful as yet is clinical, and the recipe ingredient complexity, expensive raw material price.Though CN02131250.8 patent prescription is simple, compatibility is reasonable, also is not extensive use of clinical so far.
[summary of the invention]
Therefore, people's Chinese medicine preparation that curative effect is better treated chronic conjunctivitis exists widespread demand.Up to now, also do not find the report of any relevant pharmaceutical composition of the present invention.The inventor through repeatedly research, and by zooperal repeatedly the checking, found the Chinese medicine eye medicinal of the treatment chronic conjunctivitis of determined curative effect finally, thereby finished the present invention.
This medicine is made up of Flos Lonicerae, the Radix Astragali, Radix Saposhnikoviae, Margarita and Borneolum Syntheticum, and monarch drug in the Flos Lonicerae side of being has heat-clearing and toxic substances removing, the effect of light a surname evacuation.Internal energy clear internal organs lung stomach is hot and suffocating, the heresy of external enwergy dispelling wind and heat pathogens.Wind heat is clear, and stasis is loose, white of the eye then, and red red the moving back of born of the same parents' eyelid, the puckery twinge of itching can disappear.The Radix Astragali is a ministerial drug, has invigorating the spleen and benefiting QI, sets upright the merit of poison holding; Radix Saposhnikoviae is a ministerial drug, has to deliver to dispel the wind the merit that removing dampness to relieve pain, yang invigorating make eye bright.The two and monarch drug are harmonious, auxilliary Flos Lonicerae with beneficial vigour, disperse ailment said due to cold or exposure, draw evil outer reaching, pain relieving is itched, bright eyes, the ophthalmalgia for the treatment of insufficiency of the spleen clear YANG failing to ascend, evil evil order key is red red, eyelid is unable, can not watching for a long time, watching for a long time is then ached.Margarita has liver heat removing and removes nebula, and heart-fire falls in the town, the merit that yin nourishing makes eye bright, and for ophthalmology external commonly used one of is put drops in one's eyes, " Kaibao Bencao " assists monarch drug to move back blood vessel with this product " some order, the skin cataracta of dispelling film ", removes the nebula film, and be nourshing Yin and drynsessmoistening prescription, is adjuvant drug.Borneolum Syntheticum has logical all keys, and conjunctival congestion skin nebula is gone in the stagnated fire of loosing, and the merit that makes eye bright not only be the key medicine of eye dripping, more can guide the current all keys of his medicine, works in coordination with and controls the order disease, is messenger drug.More than five medicines combinations, tool clearing away heat to improve acuity of vision altogether, move back red antipruritic effect, be used for chronic conjunctivitis, disease sees that eye is dry and astringent, itch pain, an asthenopia.To accumulate disease damp and hot or lung sense wind heat particularly suitable to belonging to spleen in the diseases such as conjunctival congestion, chronic conjunctivitis, dry astringent eye, xerosis conjunctivitis for many years.
During prescription of the present invention was formed, the weight proportion of each component was as follows:
Flos Lonicerae 10-100 part, Radix Astragali 10-100 part, Radix Saposhnikoviae 5-50 part, Margarita 2.5-7.5 part, Borneolum Syntheticum 0.5-1.5 part
The proportioning of preferred each component was as follows during prescription of the present invention was formed:
Flos Lonicerae 25-75 part, Radix Astragali 25-75 part, Radix Saposhnikoviae 15-35 part, Margarita 3-7 part, Borneolum Syntheticum 0.75-1.25 part.
Most preferred proportioning is as follows:
50 parts of Flos Loniceraes, 50 parts of the Radixs Astragali, 25 parts of Radix Saposhnikoviaes, 5 parts of Margaritas, 1 part of Borneolum Syntheticum
Preparation of the present invention is an ophthalmic preparation, and preferred preparation is solution, eye drop, apply an eye agent, eye is used unguentum, gel for eye, and most preferred preparation is an eye drop.
The present invention is as follows by the preparation method of the ophthalmic preparation of above-mentioned formulated:
A. extracting honeysuckle, the Radix Astragali and Radix Saposhnikoviae three flavor medicines, extracting in water filters, and concentrates, and adds ethanol, and placement is spent the night, and filters, and decompression filtrate recycling ethanol is not to there being the alcohol flavor, and medicinal liquid adds water, and is standby:
B. crushing pearl adds an amount of furnishing pasty state of water, adds hydrochloric acid hydrolysis and makes moltenly, leaves standstill, filter, and filtering residue reuse hydrochloric acid hydrolysis, hydrolyzed solution filters, and merges hydrolyzed solution twice, and acid is driven in heating, transfers PH closely neutral, concentrates. drying;
C. get hyaluronic acid sodium, be dissolved in water, make liquid 1;
D. get ethyl hydroxybenzoate, add the hot water dissolving, make liquid 2;
E. Borneolum Syntheticum adds water and polyoxyethylene sorbitan monoleate and grinds and make the emulsifying dissolving, adds the extracting solution of step a, the soluble pearl powder of step b, and the liquid 1 of step c, the liquid 2 of steps d, medicine acceptable carrier sodium chloride adds water, filters sterilization.
Preferred manufacturing procedure is as follows:
The above five tastes, extracting honeysuckle, the Radix Astragali and Radix Saposhnikoviae three flavor medicines, adding distil water decocts and extracts 2 times, merge decoction liquor, filter, being concentrated into relative density is the clear paste of 1.10-1.12 (50 ℃), adds ethanol precipitation, filter, placement is spent the night, and filters, and decompression filtrate recycling ethanol is to there not being the alcohol flavor, medicinal liquid adds water, and is standby; Crushing pearl adds an amount of furnishing pasty state of water, adds hydrochloric acid hydrolysis and makes moltenly, and standing demix filters, the hydrolysis of filtering residue reuse hydrochloric acid reflux, and hydrolyzed solution filters, and merges hydrolyzed solution twice, and heating in water bath drives acid, transfers PH closely neutral again, concentrates drying for standby; Other gets hyaluronic acid sodium, is dissolved in water, and ethyl hydroxybenzoate adds hot water and dissolves in right amount, and Borneolum Syntheticum adds water and the polyoxyethylene sorbitan monoleate grinding makes the emulsifying dissolving.After above-mentioned three kinds of liquid and medicinal liquid mix, add soluble pearl powder and sodium chloride successively, stirring makes dissolving, and last adding distil water is regulated pH value to 6.0-6.5 to 1000ml with 10%NaOH, mix homogeneously, filter, filter flowing steam sterilization 30 minutes again with microporous filter membrane (0.2 μ), aseptic condition filters packing down, promptly.
Eye drop of the present invention, using method be, splashes in the conjunctival sac, and one time 1-2 drips, 3-4 time on the one
Eye drop of the present invention shows good curative effect through zoopery, below is experiment content:
One, eye drop of the present invention is to the influence of rabbit chronic conjunctivitis
1. test method: 30 rabbits are divided into 5 groups at random, 6 every group (12), three experimental grouies wherein, (with the high, medium and low dosage of eye drop of the present invention); A positive controls (using the ZHENZHU MINGMU DIYANYE eye dripping); A negative control group (with eye drop solvent eye dripping of the present invention).Carry out according to the method for sunkening cord under the document employing conjunctiva.Rabbit 3% pentobarbital sodium solution 1ml/Kg auricular vein injection general anesthesia, after local anaesthesia of 0.4% hydrochloric acid Ao Buka eye drop, sunkening cord under bulbar conjunctiva elongation limbus of sclera 2mm place row bulbar conjunctiva, (scope: 180 ° of tops), the end of a thread does not expose in the conjunctival sac.Drip the medicine treatment after 24 hours, every day 3 times, each 1, continuous 3 weeks.Form observation group by 2-3 people, adopt double-blind method torch bore hole and slit lamp examination day by day, observe eye inflammation and change, it is weekly that photographing unit takes the external eyes picture.Adopt the rank test of one-dimensional order rxc table data, the pharmacodynamics data in 1-3 week is carried out statistical evaluation.
Table 1 curative effect judging standard
Every inspection index meter 0,1,2,3 minute
Curative effect synthetic determination standard: 0-0.5 is divided into healing;＞0.5-1.5 is divided into produce effects;＞1.5-2.5 is divided into improvement; 2.5 more than dividing is invalid.
Table 2 eye drop of the present invention is to the observation of curative effect result of rabbit chronic conjunctivitis
| 1 all routine numbers (eye) | 2 all routine numbers (eye) | 3 all routine numbers (eye) | |
| Group | It is invalid to cure the produce effects improvement | It is invalid to cure the produce effects improvement | It is invalid to cure the produce effects improvement |
| (mg crude drug/ml 6.55 13.1 26.2 for negative control group positive controls eye drops of the present invention | 0 0 3 9 0 1 6 5 0 0 7 5 1 1 6 4 1 3 5 3 | 1 2 6 3 6 2 4 0 3 5 3 1 7 3 2 0 7 4 1 0 | 2 5 4 1 10 2 0 0 5 7 0 0 10 2 0 0 11 1 0 0 |
| Add up to | 2 5 27 26 | 24 16 16 4 | 38 17 4 1 |
After treating for 1 week, negative control group only 3 eyes takes a turn for the better, and positive controls and the basic, normal, high dosage group of precious stilbene eye sign are all alleviated to some extent, learn by statistics and handle, difference between treatment group and the negative control group does not have significance meaning (Hc=9.2972, P=0.0541, P＞0.05); 2 weeks of continuous use, except that negative control group, each group all takes an evident turn for the better, difference between treatment group and the negative control group has highly significant meaning (Hc=15.580, P=0.0036, P＜0.01), curative effect grows from weak to strong to arrange and is followed successively by low dose group, middle dosage group, positive controls, high dose group; In 3 weeks of continuous use, except that negative control group, each group is basic recovers normal, and (Hc=24.802, P=0.001, P＜0.01), curative effect grows from weak to strong to arrange and is followed successively by low dose group, positive controls=middle dosage group, high dose group.
Two, the antiinflammatory action of eye drop of the present invention
Test method: 50 mices are divided into 5 groups at random, 10 every group, three experimental grouies wherein, (with the high, medium and low dosage eye dripping of eye drop of the present invention); A positive controls (using the diclofenac sodium eye drop eye dripping); A negative control group (with eye drop solvent eye dripping of the present invention).Adopt Mus ear swelling method to carry out according to document, male mice is applied to ear back, an animal left side with 100% dimethylbenzene (0.02ml/ only), be coated with eye drop of the present invention, positive control drug and the negative control medicine of high, medium and low dosage after half an hour respectively, every 4 hours, the dislocation of mice cervical vertebra is caused death, cut two ears, lay round auricle at same position respectively with 8mm diameter card punch from the auricle baseline, with ten thousand/scales/electronic balance weighing, deduct auris dextra with every Mus left side auricle weight and heavily be the swelling degree.Each is organized data and at first carries out test of normality, and does homogeneity test of variance.The method of the The data one factor analysis of variance of negative control group and each medication group, and do in twos and compare.Adopt mean t check between positive controls and the negative control group.Have significant difference with p＜0.05, have highly significant difference with p＜0.01.
Table 3 eye drop of the present invention is to the therapeutical effect of mice ear
| Group | Dosage (mg/kg) | Mus number (only) | Ear swelling degree (mg) | Suppression ratio (%) | The P value |
| Negative control group positive control drug eye drop of the present invention | 2.50 16.50 32.75 65.50 | 10 10 10 10 10 | 5.38±1.41 3.45±1.23 4.72±1.29 3.72±1.65 3.49±1.60 | 35.87 12.27 30.86 35.13 | ＜0.01 ＞0.05 ＜0.05 ＜0.01 |
Eye drop xylol induced mice ear swelling of the present invention has obvious inhibitory action, middle dosage group suppression ratio reaches 30.86%, compared significant difference with negative control group, the high dose group suppression ratio reaches 35.13%, compared highly significant difference with negative control group, the low dose group inhibitory action a little less than, compare there was no significant difference with negative control group; The positive controls suppression ratio reaches 35.87%, has compared highly significant difference with negative control group.
Above-mentioned result of the test shows that eye drop of the present invention has the obvious treatment effect to chronic conjunctivitis, and aspect antiinflammatory action tangible pharmacological action is arranged, for the clinical treatment chronic conjunctivitis provides certain pharmacodynamics basis.
The specific embodiment:
Further illustrate the present invention by the following examples.
The eye drop preparation of [embodiment 1] medicine of the present invention
With the three flavor medicines of Flos Lonicerae 5g, Radix Astragali 5g and Radix Saposhnikoviae 2.5g, adding distil water decocts for 20 times and extracts each 1.5 hours 2 times, merge decoction liquor, filter, be concentrated into the clear paste that relative density is 1.10-1.12 (50C), add ethanol precipitation, filter, placement is spent the night, and filters, and decompression filtrate recycling ethanol is to there not being the alcohol flavor, the medicinal liquid adding distil water is adjusted to 12.5ml, and is standby.Margarita 0.5g is ground into powder, add an amount of furnishing pasty state of water, add 1.8 times of concentrated hydrochloric acid hydrolysis make molten, standing demix, filter, filtering residue reuse 15% hydrochloric acid reflux hydrolysis 24 hours, hydrolyzed solution filters, and merges hydrolyzed solution twice, heating in water bath drives acid, reuse 10%NaOH transfers PH closely neutral, concentrates, in dry standby.O.5g other get hyaluronic acid sodium, adds the low amounts of water dissolving, and ethyl hydroxybenzoate 0.3g adds 70-80 ℃ of hot water and dissolves in right amount, and Borneolum Syntheticum 0.1g adds low amounts of water and the tween 80 grinding makes dissolving.After above-mentioned three kinds of liquid and medicinal liquid mix, add soluble pearl powder and sodium chloride 8.5g successively, stirring makes dissolving, and last adding distil water is regulated pH value to 6.0-6.5 to 1000ml with 10%Na0H, mix homogeneously, filter, filter flowing steam sterilization 30 minutes again with microporous filter membrane (0.2 μ), aseptic condition filters packing down, promptly.
The eye ointment preparation of [embodiment 2] medicine of the present invention
With the three flavor medicines of Flos Lonicerae 5g, Radix Astragali 5g and Radix Saposhnikoviae 2.5g, adding distil water decocts for 20 times and extracts each 1.5 hours 2 times, merge decoction liquor, filter, being concentrated into relative density is the clear paste of 1.10-1.12 (50 ℃), adds ethanol precipitation, filter, placement is spent the night, and filters, and decompression filtrate recycling ethanol is to there not being the alcohol flavor, the medicinal liquid adding distil water is adjusted to 12.5ml, and is standby.Margarita 0.5g is ground into powder, add an amount of furnishing pasty state of water, add 1.8 times of concentrated hydrochloric acid hydrolysis make molten, standing demix, filter, filtering residue reuse 15% hydrochloric acid reflux hydrolysis 24 hours, hydrolyzed solution filters, and merges hydrolyzed solution twice, heating in water bath drives acid, reuse 10%NaOH transfers PH closely neutral, concentrates drying for standby.Other gets ethyl hydroxybenzoate 0.3g, adds 70-80 ℃ of hot water and dissolves in right amount, and Borneolum Syntheticum 0.1g adds low amounts of water and the tween 80 grinding makes dissolving.After above-mentioned two kinds of liquid and medicinal liquid mix, add soluble pearl powder, add vaseline again: liquid paraffin: the eye pasting substrate of anhydrous lanolin=8: 1: 1 is to 1000g, and mix homogeneously, aseptic condition filter packing down, promptly.
The deposited eye agent preparation of [embodiment 3] medicine of the present invention
Method for making is added in liquid on the eye patch of non-woven fabrics under aseptic condition with embodiment 1, sealing in the aluminum of packing into the pool bag, promptly.
The eye gel preparation of [embodiment 4] medicine of the present invention
Method for making is with embodiment 2, and the eye pasting substrate of adding is used sodium carboxymethyl cellulose or hyaluronic acid sodium or polyvinyl alcohol isogel substrate instead to 1000g, mix homogeneously, and packing under the aseptic condition, promptly.
Claims (9)
1. a medicine for the treatment of chronic conjunctivitis is characterized in that making raw materials of effective components by weight ratio consists of: Flos Lonicerae 10-100 part, Radix Astragali 10-100 part, Radix Saposhnikoviae 5-50 part, Margarita 2.5-7.5 part, Borneolum Syntheticum 0.5-1.5 part.
2. the described medicine of claim 1, described proportioning is Flos Lonicerae 25-75 part, Radix Astragali 25-75 part, Radix Saposhnikoviae 15-35 part, Margarita 3-7 part, Borneolum Syntheticum 0.75-1.25 part.
3. the described medicine of claim 1,50 parts of described proportioning Flos Loniceraes, 50 parts of the Radixs Astragali, 25 parts of Radix Saposhnikoviaes, 5 parts of Margaritas, 1 part of Borneolum Syntheticum.
4. the arbitrary described medicine of claim 1-3 is an ophthalmic preparation.
5. the described medicine of claim 4 is solution, eye drop, applies an eye agent, eye with unguentum or gel for eye.
6. the described medicine of claim 5 is an eye drop.
7. the preparation method of the described medicine of claim 6 is characterized in that, prepares according to the following step:
A. extracting honeysuckle, the Radix Astragali and Radix Saposhnikoviae three flavor medicines, extracting in water filters, and concentrates, and adds ethanol, and placement is spent the night, and filters, and decompression filtrate recycling ethanol is not to there being the alcohol flavor, and medicinal liquid adds water, and is standby;
B. crushing pearl adds an amount of furnishing pasty state of water, adds hydrochloric acid hydrolysis and makes moltenly, leaves standstill, filter, and filtering residue reuse hydrochloric acid hydrolysis, hydrolyzed solution filters, and merges hydrolyzed solution twice, and acid is driven in heating, transfers PH closely neutral, concentrates drying;
C. get hyaluronic acid sodium, be dissolved in water, make liquid 1;
D. get ethyl hydroxybenzoate, add the hot water dissolving, make liquid 2;
E. Borneolum Syntheticum adds water and polyoxyethylene sorbitan monoleate and grinds and make the emulsifying dissolving, adds the extracting solution of step a, the soluble pearl powder of step b, the liquid 1 of step c, the liquid 2 of steps d, and sodium chloride.
8. the described preparation method of claim 7 is characterized in that, the medicine acceptable carrier among the step e is a sodium chloride.
9. the application of the arbitrary described medicine of claim 1-6 in the medicine of preparation treatment chronic conjunctivitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100908597A CN1311842C (en) | 2005-08-18 | 2005-08-18 | Medicine for treating chronic conjunctivitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100908597A CN1311842C (en) | 2005-08-18 | 2005-08-18 | Medicine for treating chronic conjunctivitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1730022A CN1730022A (en) | 2006-02-08 |
| CN1311842C true CN1311842C (en) | 2007-04-25 |
Family
ID=35962468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100908597A Expired - Fee Related CN1311842C (en) | 2005-08-18 | 2005-08-18 | Medicine for treating chronic conjunctivitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1311842C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103169760A (en) * | 2013-03-12 | 2013-06-26 | 翁捷 | Medicinal composition for treating chronic conjunctivitis |
| CN103169759A (en) * | 2013-03-12 | 2013-06-26 | 张成全 | Chinese medicinal composition for treating chronic conjunctivitis and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1061262C (en) * | 1998-08-19 | 2001-01-31 | 刘毅刚 | Eye drops for treating conjunctivitis and preparing process thereof |
| CN1172711C (en) * | 2002-09-19 | 2004-10-27 | 安徽省双科药业有限公司 | Chinese medicine preparation for curing chronic conjunctivitis |
-
2005
- 2005-08-18 CN CNB2005100908597A patent/CN1311842C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1061262C (en) * | 1998-08-19 | 2001-01-31 | 刘毅刚 | Eye drops for treating conjunctivitis and preparing process thereof |
| CN1172711C (en) * | 2002-09-19 | 2004-10-27 | 安徽省双科药业有限公司 | Chinese medicine preparation for curing chronic conjunctivitis |
Non-Patent Citations (3)
| Title |
|---|
| 中医眼科外用药研究新进展一全国中医眼科外用药学术研讨会概要 肖空翔，中医药信息 1992 * |
| 珍珠眼膏的研制及应用 王林，中成药，第15卷第8期 1992 * |
| 珍珠眼膏的研制及应用 王林，中成药，第15卷第8期 1992;中医眼科外用药研究新进展一全国中医眼科外用药学术研讨会概要 肖空翔，中医药信息 1992 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1730022A (en) | 2006-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101716214B (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| CN101564375A (en) | Chinese medicinal in situ forming eye gel | |
| CN102631558A (en) | Medicament for treating eye disease and preparation method of medicament | |
| CN102357196B (en) | External traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof | |
| CN102362924B (en) | Medicinal composition for treating ophthalmic diseases and preparation method thereof | |
| CN105106318B (en) | A kind of Chinese medicine composition and preparation method thereof for treating xerophthalmia | |
| CN101284048A (en) | Formulations for effectively improving hypometropia, asthenopia, cataract, eyeground pathological changes | |
| CN104971304A (en) | Xerophthalmia treatment medicine | |
| CN1311842C (en) | Medicine for treating chronic conjunctivitis | |
| CN100411660C (en) | Chinese medicine composition for treating optic atrophy and preparing method therefor | |
| CN104906220A (en) | Traditional Chinese medicine for treating herpes zoster and herpes simplex viral keratitis | |
| CN1160091C (en) | Medicine for treating ophthalmopathy | |
| CN104367832A (en) | Compound dendrobe eye drops for treating xerophthalmia and preparation method thereof | |
| CN114010591A (en) | Externally-applied traditional Chinese medicine gel paste for treating asthenopia and preparation method thereof | |
| CN103040986A (en) | Ophthalmic gel for treating uveitis and preparation method of ophthalmic gel | |
| CN106362089A (en) | External medicine for treating eye diseases | |
| CN1056292C (en) | Eyesight granule and its compounding process | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN102920911B (en) | Traditional Chinese medicine for treating keratoconjunctivitis sicca and preparation method thereof | |
| CN105902686A (en) | In-situ gel eyewash containing nano-carbon crystals and preparation method thereof | |
| CN102940753B (en) | Pills for treating glaucoma and preparation method | |
| CN1400004A (en) | Chinese medicine preparation for curing chronic conjunctivitis | |
| CN109288970A (en) | It is a kind of with it is nourishing liver and kidney, clear liver and improve vision, the integration of drinking and medicinal herbs composition of Yin-nourishing and body fluid promoting function and preparation method thereof | |
| CN112336838A (en) | Traditional Chinese medicine formula eye drop for treating xerophthalmia and preparation method thereof | |
| CN103550357B (en) | A kind of control muscae volitantes collyrium and its production and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |